Brief: Sellas Receives FDA Orphan Drug Designation For Sls009 For Treatment Of Peripheral T-Cell Lymphomas
21/12/2023 14:40
Dec 21 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR SLS009 FOR
TREATMENT OF PERIPHERAL T-CELL LYMPHOMAS
* SELLAS LIFE SCIENCES GROUP INC: PHASE 1B/2 STUDY IN PTCL
ONGOING
WITH TOP LINE DATA EXPECTED IN 1H 2024
Source text for Eikon: ID:nGNX1S7M2X
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses